Omnicell (NASDAQ:OMCL) EVP Nnamdi Njoku Sells 3,090 Shares

Omnicell, Inc. (NASDAQ:OMCL) EVP Nnamdi Njoku sold 3,090 shares of the firm’s stock in a transaction on Monday, May 18th. The stock was sold at an average price of $43.22, for a total value of $133,549.80. Following the transaction, the executive vice president directly owned 154,785 shares of the company’s stock, valued at $6,689,807.70. The trade was a 1.96% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Omnicell Stock Performance

Omnicell stock opened at $43.82 on Wednesday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.29 and a current ratio of 1.50. The stock has a fifty day moving average of $37.71 and a two-hundred day moving average of $40.60. The company has a market capitalization of $1.99 billion, a price-to-earnings ratio of 99.59, a PEG ratio of 1.12 and a beta of 0.96. Omnicell, Inc. has a fifty-two week low of $26.84 and a fifty-two week high of $55.00.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings results on Tuesday, April 28th. The company reported $0.55 earnings per share for the quarter, topping the consensus estimate of $0.33 by $0.22. The company had revenue of $309.88 million during the quarter, compared to the consensus estimate of $304.02 million. Omnicell had a return on equity of 4.00% and a net margin of 1.67%.Omnicell’s revenue was up 14.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.26 earnings per share. Omnicell has set its FY 2026 guidance at 1.800-2.000 EPS and its Q2 2026 guidance at 0.400-48.000 EPS. On average, analysts anticipate that Omnicell, Inc. will post 1.31 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. boosted its holdings in Omnicell by 83.6% in the fourth quarter. Assenagon Asset Management S.A. now owns 258,231 shares of the company’s stock valued at $11,698,000 after acquiring an additional 117,556 shares during the last quarter. Peregrine Capital Management LLC acquired a new position in Omnicell in the fourth quarter valued at $4,804,000. Dynamic Technology Lab Private Ltd boosted its holdings in Omnicell by 345.9% in the third quarter. Dynamic Technology Lab Private Ltd now owns 31,890 shares of the company’s stock valued at $971,000 after acquiring an additional 24,738 shares during the last quarter. Dana Investment Advisors Inc. acquired a new position in Omnicell in the fourth quarter valued at $3,445,000. Finally, AlphaQuest LLC boosted its holdings in Omnicell by 388.4% in the third quarter. AlphaQuest LLC now owns 24,231 shares of the company’s stock valued at $738,000 after acquiring an additional 19,270 shares during the last quarter. Institutional investors and hedge funds own 97.70% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on OMCL. Bank of America raised Omnicell from a “neutral” rating to a “buy” rating and set a $70.00 price target for the company in a research report on Wednesday, February 4th. KeyCorp raised their price target on Omnicell from $60.00 to $70.00 and gave the stock an “overweight” rating in a research report on Tuesday, April 28th. Zacks Research raised Omnicell from a “hold” rating to a “strong-buy” rating in a research report on Friday, May 1st. Wall Street Zen raised Omnicell from a “buy” rating to a “strong-buy” rating in a research report on Sunday, May 10th. Finally, Benchmark reaffirmed a “buy” rating on shares of Omnicell in a research report on Friday, March 13th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, Omnicell has an average rating of “Buy” and an average price target of $59.86.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.